RT Journal Article
SR Electronic
T1 Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.01.21261297
DO 10.1101/2021.08.01.21261297
A1 Sheikh-Mohamed, Salma
A1 Isho, Baweleta
A1 Chao, Gary Y.C.
A1 Zuo, Michelle
A1 Cohen, Carmit
A1 Lustig, Yaniv
A1 Nahass, George R.
A1 Salomon-Shulman, Rachel E.
A1 Blacker, Grace
A1 Fazel-Zarandi, Mahya
A1 Rathod, Bhavisha
A1 Colwill, Karen
A1 Jamal, Alainna
A1 Li, Zhijie
A1 de Launay, Keelia Quin
A1 Takaoka, Alyson
A1 Garnham-Takaoka, Julia
A1 Patel, Anjali
A1 Fahim, Christine
A1 Paterson, Aimee
A1 Li, Angel Xinliu
A1 Haq, Nazrana
A1 Barati, Shiva
A1 Gilbert, Lois
A1 Green, Karen
A1 Mozafarihashjin, Mohammad
A1 Samaan, Philip
A1 Budylowski, Patrick
A1 Siqueira, Walter L.
A1 Mubareka, Samira
A1 Ostrowski, Mario
A1 Rini, James M.
A1 Rojas, Olga L.
A1 Weissman, Irving L.
A1 Tal, Michal Caspi
A1 McGeer, Allison
A1 Regev-Yochay, Gili
A1 Straus, Sharon
A1 Gingras, Anne-Claude
A1 Gommerman, Jennifer L.
YR 2022
UL http://medrxiv.org/content/early/2022/01/02/2021.08.01.21261297.abstract
AB Although SARS-CoV-2 infects the upper respiratory tract, we know little about the amount, type, and kinetics of antibodies (Ab) generated at this site in response to intramuscular COVID-19 vaccination, and whether these Ab protect against subsequent “breakthrough” infections. We collected longitudinal serum and saliva samples from participants receiving two doses of mRNA COVID-19 vaccines over a 6-month period and measured the relative level of anti-Spike and anti-Receptor Binding Domain (RBD) Ab. We detected anti-Spike/RBD IgG and IgA and associated secretory component in the saliva of most participants receiving 1 dose of mRNA vaccine. Administration of a second dose of mRNA boosted the IgG but not the IgA response, with only 30% of participants remaining positive for IgA at this timepoint. At 6 months post-dose 2, these participants exhibited greatly diminished anti-Spike/RBD IgG and IgA levels concomitant with a reduction in neutralizing activity in the saliva, although the level of secretory component associated anti-Spike was less susceptible to decay. Examining two prospective cohorts of subjects that were monitored for infections post-vaccination, we found that participants who were subsequently infected with SARS-CoV-2 had lower levels of vaccine-induced serum anti-Spike/RBD IgA at 2-4 weeks post-dose 2 compared to participants who did not experience an infection, whereas IgG levels were comparable between groups. These data emphasize the importance of developing COVID-19 vaccines that elicit a durable IgA response.One-Sentence Summary Our study delves into whether intra-muscular mRNA vaccination regimes confer a local IgA response in the oral cavity and whether the IgA response is associated with protection against breakthrough infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by an Ontario Together province of Ontario grant to JG and ACG and a Foundation grant from the Canadian Institutes of Health Research to JG (Fund #15992). Funding for the LTCH cohort was provided through a Canada COVID-19 Immunity Task force grant (to SS, AM, MO, ACG and JG). Funding for initial development of the assays in the Gingras lab was provided through generous donations from the Royal Bank of Canada (RBC) and the Krembil Foundation to the Sinai Health System Foundation. The robotics equipment used is housed in the Network Biology Collaborative Centre at the Lunenfeld-Tanenbaum Research Institute, a facility supported by Canada Foundation for Innovation funding, by the Ontarian Government and by Genome Canada and Ontario Genomics (OGI-139).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Mount Sinai Hospital Research Ethics Board (REB) granted approval for recruiting LTCH participants located in Toronto for blood and saliva collection and for conducting serum ELISAs at the Lunenfeld-Tanenbaum Research Institute (study number: 20-0339-E). The University of Toronto REB granted approval for subject recruitment to collect blood and saliva samples and for conducting saliva ELISAs (study number: 23901). The University of Saskatchewan REB granted approval for saliva sample collection during the pre-COVID era (study number: BIO-USask-1579). The Sheba Medical Center REB granted approval for subject recruitment to collect blood and for conducting ELISAs (study number: 8008-20-SMC). Cohorts are further described in Tables S1-S6 and supplemental methods in the Appendix.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data will be available upon reasonable request.